# An Extension of the TG1101-RMS201 Trial

> **NCT03381170** · PHASE2 · COMPLETED · sponsor: **TG Therapeutics, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Ublituximab

## Key facts

- **NCT ID:** NCT03381170
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2022-11-11
- **Final completion:** 2022-11-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381170, "An Extension of the TG1101-RMS201 Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03381170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*